The European Commission has granted conditional approval for Sanofi's Rezurock (belumosudil) to treat chronic graft-versus-host disease (GVHD) in adults and children aged 12 and above with limited treatment options. This approval follows positive clinical trial results showing a 74% overall response rate in patients who had failed at least two prior therapies. Rezurock offers a new option for a serious condition affecting up to half of stem cell transplant patients, with ongoing studies to confirm long-term benefits and explore use in younger children and other indications. Sanofi will conduct further confirmatory trials as part of the conditional approval requirements.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
